TAPISTRY (BO41932) is a Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in participants with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are tumor mutational burden (TMB)-high as identified by a validated next-generation sequencing (NGS) assay.
Participants with solid tumors will be treated with a drug or drug regimen tailored to their NGS assay results at screening. Participants will be assigned to the appropriate cohort based on their genetic alteration(s). Cohort K of TAPISTRY will enroll patients with RET fusion-positive solid tumors (excluding non-small cell lung cancer patients).
If you would like more information about this study, please visit this website or, for patients in the USA, call 888-662-6728 (5 am - 5 pm PST).